Hospitalization and Death in the First 30 days After Outpatient Lower Extremity Arterial Stenting

Abstract

To compare the safety of outpatient versus inpatient endovascular treatment of lower extremity arterial disease (LEAD) using real-life data. Materials and MethodsThis retrospective observational study used real-life data from the French national health data information system on adult patients who underwent stenting for LEAD between 2013 and 2016. The outcomes of interest were all-cause mortality, all-cause hospitalization, planned hospitalization, and unplanned hospitalization at day 3 and day 30 after the index endovascular intervention for LEAD revascularization. A propensity score was used to control for indication bias. Outcome rates in outpatient and inpatient settings were compared with the Poisson regression model. Sensitivity analyses were performed by varying the definition of the outcomes of interest. ResultsDuring the study period, 26 715 interventions were performed among which 2 819 (10.6%) were in outpatient settings. Outpatients were slightly younger than inpatients (64.73 ±10.68 versus 68.10 ±11.50, respectively). The percentage of women patients was similar: 19.8% in the outpatient group and 27.2% in the inpatient group. Within 30 days after discharge, 73 patients (.31%) and 2 (.07%) patients (p = .02) died in the inpatient group and outpatient group, respectively. The death and rehospitalization rate were similar: 3.8 and 3.5 per 1 000 person-months for inpatients and outpatients, respectively. No difference was observed after adjusting for patients' case-mix in the regression model (RR = .99; 95% CI [.82-1.19]).Conclusions Outpatient stenting for LEAD did not present any additional risk of early postoperative rehospitalization or death compared with inpatient stenting.

Development of a Flexible and Stretchable Wireless Pressure Sensor- Integrated Smart Stent for Continuous Monitoring of Cardiovascular Function

“…Bioabsorbable stents and bioabsorbable drug-eluting stents have been proposed to reduce the adverse effects (Zablah et al 2022). Despite signi cant advancements in stent technology, several issues, and complications such as in-stent restenosis, stent thrombosis and re-narrowing the blood arteries may still arise after stent implantation or resorb the polymer stent within the body (Li et al 2021;Jan et al 2022;Haidegger et al 2021).…”

Continuous monitoring of cardiovascular function with a smart stent incorporating a flexible and stretchable wireless pressure sensor

“…Bioabsorbable stents and bioabsorbable DES have been proposed as potential solutions to minimize adverse effects [7]. Despite significant advancements in stent technology, issues and complications such as in-stent restenosis, stent thrombosis, and re-narrowing of blood vessels may still arise after stent implantation or resorption of the polymer stent within the body [8][9][10]. For instance, thermoplastic polymer like poly lactic acid (PLA), polycaprolactone (PCL), polyglycolic acid (PGA) and poly-Llactic acid (PLLA) emerging as suitable materials for crafting stents using 3D printing technology.…”